DermBiont's mission is to become the world's leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root cause of skin diseases with biotherapeutics that repair an imbalance of the microbiome as well as through the development of targeted small molecule therapeutics with well-defined mechanisms of action. DermBiont's biotherapeutics discovery team leverages computational biology and a proprietary bioinformatics platform to identify clinically meaningful dysbiosis related to common skin diseases and mines a curated library of microbes to build a pipeline of products to treat identified dysbiosis across indications.